AUSTEDO was studied in a diverse patient population reflective of clinical practice1-4

Efficacy and safety were evaluated in adult patients with tardive dyskinesia (TD) ages 18 to 80 with1:

A broad range of primary conditions2-4

AUSTEDO was studied in a diverse patient population reflective of clinical practice: 15% depression, 3% gastrointestinal disorders, 43% schizophrenia, 15% schizoaffective disorder, 24% bipolar disorder.

Comorbid conditions4

  • Cardiovascular disorders
  • Metabolism/nutritional disorders, including diabetes
  • Lipid disorders

Regimens of concomitant medications, which remained stable throughout the studies1,2,4

  • Antidepressants at baseline: 56% of patients
  • Antipsychotics
  • Atypical: 64% of patients
  • Typical or combination: 12% of patients
  • None at baseline: 24% of patients

Faces of Tardive Dyskinesia (TD) icon.

3 hypothetical patient case studies, presented by specialists

Watch: Brian

A patient with bipolar disorder, who has had his routine disrupted by TD play-circle.svg play-circle-active.svg

Watch: Lisa

A patient with schizophrenia, whose movements are starting to impact her time with her family

Watch: Patricia

A patient with major depressive disorder, who is also taking an antihypertensive play-circle.svg play-circle-active.svg

REFERENCES: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 2. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88(21):2003-2010. 3. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. 4. Data on file. North Wales, PA: Teva Neuroscience, Inc.